Inclusion Criteria:

* ≥ 18 years of age at time of informed consent
* Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or locally advanced and unresectable that is ROR1+ by central laboratory immunohistochemistry (IHC)
* Measurable disease including a target lesion and an additional lesion for biopsy
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Adequate organ and marrow function
* Women of childbearing potential must have a negative pregnancy test at screening
* All participants must agree to practice highly effective methods of contraception

Exclusion Criteria:

* Prior treatment with any adoptive T-cell therapy or anti-ROR1 therapy
* Prior solid organ transplantation
* Active, untreated brain metastasis or leptomeningeal disease; stable, treated brain involvement by disease is allowed
* Untreated or active infection at the time of screening or leukapheresis
* HIV-positive, HTLV-1-positive, active acute or chronic HBV or HCV, or active tuberculosis
* Impaired cardiac function or clinically significant cardiac disease
* Uncontrolled pleural or pericardial effusion
* Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis
* Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors
* Pregnant or lactating/nursing women

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/12/2024. Questions regarding updates should be directed to the study team contact.